TY - JOUR
T1 - Histone demethylase KDM5B as a therapeutic target for cancer therapy
AU - Jose, Anmi
AU - Shenoy, Gautham G.
AU - Rodrigues, Gabriel Sunil
AU - Kumar, Naveena A.N.
AU - Munisamy, Murali
AU - Thomas, Levin
AU - Kolesar, Jill
AU - Rai, Ganesha
AU - Rao, Praveen P.N.
AU - Rao, Mahadev
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/8
Y1 - 2020/8
N2 - Lysine-specific demethylase 5B (KDM5B/PLU1/JARID1B) is found to be overexpressed in numerous malignancies, including breast, lung, skin, liver, and prostate cancer. Identification of molecules targeting the KDM5B enzyme could be a potential lead in cancer research. Although many KDM5B inhibitors with promising outcomes have been developed so far, its further application in clinical practice is limited due to toxicity and lack of target specificity. Here, we summarize the significance of targeting KDM5B in anticancer therapy and report the molecular docking studies of some known anti-viral agents, decitabine, entecavir, abacavir, penciclovir, and 3-deazaneplanocin A in the catalytic domain JmjC of KDM5B. These studies show the repurposing potential of identified anti-viral agents in cancer therapy.
AB - Lysine-specific demethylase 5B (KDM5B/PLU1/JARID1B) is found to be overexpressed in numerous malignancies, including breast, lung, skin, liver, and prostate cancer. Identification of molecules targeting the KDM5B enzyme could be a potential lead in cancer research. Although many KDM5B inhibitors with promising outcomes have been developed so far, its further application in clinical practice is limited due to toxicity and lack of target specificity. Here, we summarize the significance of targeting KDM5B in anticancer therapy and report the molecular docking studies of some known anti-viral agents, decitabine, entecavir, abacavir, penciclovir, and 3-deazaneplanocin A in the catalytic domain JmjC of KDM5B. These studies show the repurposing potential of identified anti-viral agents in cancer therapy.
KW - Cancer
KW - Histone modification
KW - Inhibitor
KW - KDM5B
KW - Molecular docking
KW - Repurposing
UR - http://www.scopus.com/inward/record.url?scp=85088990570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088990570&partnerID=8YFLogxK
U2 - 10.3390/cancers12082121
DO - 10.3390/cancers12082121
M3 - Review article
AN - SCOPUS:85088990570
SN - 2072-6694
VL - 12
SP - 1
EP - 16
JO - Cancers
JF - Cancers
IS - 8
M1 - 2121
ER -
